TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26008133

Group type: EXPERIMENTAL
Intervention: (3)He MRI with abnormally elevated ventilation defect percent (VDP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal VDP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation of whole lung and lobar VDP with regional (3)He ADC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regional VDP correlation with CT airway morphology measurements
Number of subjects: 60
Study: 22673738

Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose macrolides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21384253

Group type: EXPERIMENTAL
Intervention: Homogenised spinach (225 g/day/person)
Number of subjects: 8
Study: 19136455

Group type: EXPERIMENTAL
Intervention: Destruction of lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnostic only operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excisional surgery for rectovaginal endometriosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative surgery for symptomatic endometriosis
Number of subjects: 0
Study: 16364015

Group type: EXPERIMENTAL
Intervention: LIF concentration in pregnant women (42 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: LIF concentration in non-pregnant women (66 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LIF concentration in women with ongoing pregnancy (34 ongoing pregnancy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: LIF concentration in women with miscarriage (8 miscarriage)
Number of subjects: 120
Study: 15342304

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 10899371

Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9017547

Group type: EXPERIMENTAL
Intervention: Tea bag compress
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Water compress
Number of subjects: 65

Group type: COMPARATOR
Intervention: No compress
Number of subjects: 65
Study: 8393676

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 2434792

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 mg p.o. q.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg p.o. q.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo not explicitly mentioned)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril (both doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12
Study: 29075824

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Arm B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Everolimus (Arm E)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Everolimus (dual-therapy)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dual-therapy in normal liver (Arm E)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dual-therapy in normal liver (Arm B)
Number of subjects: 27
Study: 26541479

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24726190

Group type: EXPERIMENTAL
Intervention: Simple and advanced methods of gait assessment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (11 weeks)
Number of subjects: 21
Study: 23789281

Group type: EXPERIMENTAL
Intervention: General anesthesia with off-pump surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined general and high thoracic epidural anesthesia with off-pump surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: General anesthesia with on-pump surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined general and high thoracic epidural anesthesia with on-pump surgery
Number of subjects: 82
Study: 20002546

Group type: EXPERIMENTAL
Intervention: Use of the REFLECT statement for livestock trials
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modification of CONSORT checklist items
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Web-based survey conducted before the meeting
Number of subjects: 24
Study: 19015462

Group type: EXPERIMENTAL
Intervention: Standardized lecture about colon cancer lymph node assessment delivered by an expert opinion leader
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Academic detailing of a local opinion leader and a toolkit
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (21 hospitals) receiving only the standardized lecture
Number of subjects: 42
Study: 16882058

Group type: EXPERIMENTAL
Intervention: 25 mg/day naftopidil (Group LD)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 75 mg/day naftopidil (Group HD)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 153
Study: 14661012

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1500 mg, starting the evening before angiography and given every 12 hours for 4 doses
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) and Placebo
Number of subjects: 96
Study: 10721816

Group type: EXPERIMENTAL
Intervention: PVX (plasma volume expansion with dextran (6%) or Pentaspan (10%))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PVX
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON (control condition)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PVX and CON
Number of subjects: 8
Study: 8795667

Group type: EXPERIMENTAL
Intervention: Lysine aspirin 900 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium salicylate 800 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 9.5% saline with indomethacin 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3% saline
Number of subjects: 15

Group type: COMPARATOR
Intervention: 10% saline
Number of subjects: 15
Study: 1479532

Group type: EXPERIMENTAL
Intervention: Various design and analysis methods in periodontal clinical trials
Number of subjects: 0
Study: 6600677

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg
Number of subjects: 12
Study: 30878329

Group type: EXPERIMENTAL
Intervention: Standard training plus additional weekly simulation training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard training plus additional weekly simulation training (standardized to supervisor's performance)
Number of subjects: 0
Study: 28366341

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy including parent involved play (CBT-PIP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-directive treatment (TEPT; triadic expressive play therapy)
Number of subjects: 90
Study: 27092916

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection prior to implant placement
Number of subjects: 26

Group type: COMPARATOR
Intervention: No Botulinum toxin type A injection (Control group)
Number of subjects: 26
Study: 24703078

Group type: EXPERIMENTAL
Intervention: BROADLINE(®) at 0.12 mg/kg body weight
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated cats)
Number of subjects: 16
Study: 22116799

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics (e.g., erythromycin, azithromycin)
Number of subjects: 235

Group type: COMPARATOR
Intervention: No macrolide antibiotics (Control)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics
Number of subjects: 235

Group type: COMPARATOR
Intervention: Fluoroquinolone antibiotics (n = 90)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Cephalosporin antibiotics (n = 93)
Number of subjects: 235
Study: 20661811

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 100
Study: 17612356

Group type: EXPERIMENTAL
Intervention: CAI-rehab (rehabilitation program for CAI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CAI-control (control group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 48
Study: 15258224

Group type: EXPERIMENTAL
Intervention: Active rTMS (15 Hz rTMS for 10 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 42
Study: 12465006

Group type: EXPERIMENTAL
Intervention: Open reduction with internal fixation (ORIF) and intermaxillary wire fixation (IMF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Open reduction with internal fixation (ORIF) without intermaxillary wire fixation (IMF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both treatment groups (ORIF with IMF and ORIF without IMF)
Number of subjects: 31
Study: 10211915

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (THP) dose reduction by 1 mg every 2 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no dose reduction)
Number of subjects: 75
Study: 8561482

Group type: EXPERIMENTAL
Intervention: Neophilic model (who chose mostly novel foods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neophobic model (who chose mostly familiar foods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to neophilic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling manipulation
Number of subjects: 0
Study: 2371034

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 31555

Group type: EXPERIMENTAL
Intervention: Supristol (co-trifamole)
Number of subjects: 163

Group type: COMPARATOR
Intervention: co-trimoxazole
Number of subjects: 163
Study: 30643648

Group type: EXPERIMENTAL
Intervention: Community perceptions towards pregnant women with disabilities (PWDs)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Educational status
Number of subjects: 405

Group type: COMPARATOR
Intervention: Perceptions of disability causes
Number of subjects: 405
Study: 26892333

Group type: EXPERIMENTAL
Intervention: Provider-delivered education/counseling intervention
Number of subjects: 4009

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4009
Study: 24705623

Group type: EXPERIMENTAL
Intervention: Cilostazol and probucol combination therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cilostazol monotherapy
Number of subjects: 119
Study: 22089058

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 260
Study: 20043296

Group type: EXPERIMENTAL
Intervention: advanced practice nurse‐delivered, culturally tailored, in‐home psychotherapy intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 80
Study: 19032525

Group type: EXPERIMENTAL
Intervention: Cinacalcet (administered for 7-14 months)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 8
Study: 15726857

Group type: EXPERIMENTAL
Intervention: Intervention group with clinical recommendations from the sentinel system
Number of subjects: 39462

Group type: EXPERIMENTAL
Intervention: Intervention group with communicated recommendations
Number of subjects: 39462

Group type: EXPERIMENTAL
Intervention: Entire intervention group
Number of subjects: 39462

Group type: EXPERIMENTAL
Intervention: Intervention cost
Number of subjects: 39462
Study: 11238152

Group type: EXPERIMENTAL
Intervention: Peer led programme for asthma education (Triple A Program)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study: 9512244

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) of metabolites in seminal plasma
Number of subjects: 0
Study: 7852659

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 209

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 209
Study: 3290711

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 194

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 194
Study: 1984829

Group type: COMPARATOR
Intervention: 7-3 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3 plus etoposide 75 mg/m2 on days 1 to 7)
Number of subjects: 264

Group type: COMPARATOR
Intervention: 7-3 therapy
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy
Number of subjects: 264

Group type: COMPARATOR
Intervention: 7-3 therapy (subset analysis for patients younger than 55 years)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy (subset analysis for patients younger than 55 years)
Number of subjects: 264
Study: 32044

Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clemastine 3 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31710974

Group type: EXPERIMENTAL
Intervention: Just-in-time training program
Number of subjects: 534

Group type: COMPARATOR
Intervention: Pre-intervention Medical Emergency Team call frequency
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Post-intervention Medical Emergency Team call frequency
Number of subjects: 534
Study: 30507563

Group type: EXPERIMENTAL
Intervention: Supervised Rehabilitation (SR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home-Based Rehabilitation (HBR)
Number of subjects: 30
Study: 28739335

Group type: EXPERIMENTAL
Intervention: Individualized diet and physical exercise programme supervised by a dietician
Number of subjects: 41

Group type: COMPARATOR
Intervention: No previous intervention (control group)
Number of subjects: 41
Study: 26437449

Group type: EXPERIMENTAL
Intervention: Multi-dimensional and inter-sectoral intervention program including therapy simplification and individualized patient education during hospital stay and up to three months after discharge, with subsequent phone calls after discharge.
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Multi-dimensional and inter-sectoral intervention program
Number of subjects: 269

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 269
Study: 22856678

Group type: EXPERIMENTAL
Intervention: Toothbrushing immediately after bleaching
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrushing one hour after bleaching
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrushing two hours after bleaching
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no brushing after bleaching)
Number of subjects: 80
Study: 21883123

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg.kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine 100 μg.kg(‐1)
Number of subjects: 60
Study: 19609165

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) training for 8 weeks, including 3 sets of daily fast and slow contractions in various positions and weekly motivational calls.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group with no intervention or contact during the intervention period.
Number of subjects: 41
Study: 17716312

Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD; 20 mg bid)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 14755150

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (specifics not provided)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily for 12 months
Number of subjects: 71
Study: 11580089

Group type: EXPERIMENTAL
Intervention: OHIP 14 in interview format
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: OHIP 14 in questionnaire format
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: OIDP in questionnaire format
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Both questionnaires
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: OHIP 14
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: OIDP
Number of subjects: 183
Study: 9853852

Group type: EXPERIMENTAL
Intervention: Intramesosalpingeal injection of 20 IU oxytocin diluted to 20 ml with saline solution
Number of subjects: 25

Group type: COMPARATOR
Intervention: 20 ml saline solution (control)
Number of subjects: 25
Study: 8014707

Group type: EXPERIMENTAL
Intervention: Patient-triggered, flow-synchronized ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional time-cycled, pressure-limited ventilation
Number of subjects: 30
Study: 2687142

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night (single dose)
Number of subjects: 339
Study: 4559027

Group type: EXPERIMENTAL
Intervention: Tyramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31443993

Group type: EXPERIMENTAL
Intervention: Co-Administration group (RZV dose 1 and Tdap at Day 0, RZV dose 2 at Month 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Tdap at Day 0, RZV dose 1 at Month 2, RZV dose 2 at Month 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-Administration group and Control group
Number of subjects: 0
Study: 29216285

Group type: EXPERIMENTAL
Intervention: HI(R)T
Number of subjects: 80
Study: 25026944

Group type: EXPERIMENTAL
Intervention: Inner relationship focusing (20‐h course followed by 5 months of weekly sessions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 23625433

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/d for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21803260

Group type: EXPERIMENTAL
Intervention: Miniscrew between the premolar and the molar (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Miniscrew between the premolars (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 36
Study: 19833787

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Structured clinical management (SCM)
Number of subjects: 134
Study: 17091656

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SMP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single Bond (SB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APL)
Number of subjects: 60
Study: 14741680

Group type: EXPERIMENTAL
Intervention: rtfMRI-based training with feedback information about activation levels in the somatomotor cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving similar training without rtfMRI information
Number of subjects: 0
Study: 11583750

Group type: EXPERIMENTAL
Intervention: Radical nephrectomy plus interferon-alfa-based immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Interferon alfa alone
Number of subjects: 83
Study: 11263387

Group type: EXPERIMENTAL
Intervention: EMB regimen (2E3H3R3Z3/4H3R3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SM regimen (2S3H3R3Z3/4H3R3)
Number of subjects: 0
Study: 7869303

Group type: EXPERIMENTAL
Intervention: 20 mg pamidronate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40 mg pamidronate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2450722

Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy with 5-FU via the recanalized umbilical vein in patients without liver metastases
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intraportal adjuvant chemotherapy after resection of liver metastases
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy in patients with unresectable liver metastases
Number of subjects: 3
Study: 31608968

Group type: EXPERIMENTAL
Intervention: Computer assisted training via a training website
Number of subjects: 62

Group type: COMPARATOR
Intervention: Training guidebook with the same content as the website
Number of subjects: 62
Study: 30249314

Group type: EXPERIMENTAL
Intervention: Cottage cheese (CC) - 30 g of protein, 10 g of carbohydrate, 0 g of fat
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Casein protein (CP) - isoenergetic/isonitrogenous liquid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL) - 0 kJ
Number of subjects: 10
Study: 27163237

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Dexamethasone 0.7 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 243

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 243
Study: 25009252

Group type: EXPERIMENTAL
Intervention: Tonic pain during locomotor adaptation task (capsaicin cream applied around the ankle) on Day 1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pain-free locomotor adaptation task on Day 2
Number of subjects: 30
Study: 22490095

Group type: EXPERIMENTAL
Intervention: 3D training
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2D training
Number of subjects: 73
Study: 20957010

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 18624971

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 307